Deals channel feed

Take­da eyes path­way to nat­ur­al killer ther­a­pies, tee­ing up $100M to part­ner with KSQ for its CRISPR-screened mol­e­cules

5 years ago
Cell/Gene Tx

Am­gen ponies up $240M for Michi­gan dis­cov­ery out­fit's den­drit­ic cell tar­get­ing mol­e­cules for au­toim­mune dis­or­ders

5 years ago

On a mis­sion to 'u­ni­fy' drug dis­cov­ery and cell-line de­vel­op­ment, Ab­Sci ac­quires AI out­fit De­n­ovi­um

5 years ago
AI

Dou­bling down on on­col­o­gy, Sanofi buys in­to a new check­point in­hibitor with a $125M down pay­ment

5 years ago

Boehringer In­gel­heim en­lists a UK start­up in a mile­stone-heavy quest for 'dark anti­gen­s'

5 years ago

No­var­tis brings BeiGene's promis­ing check­point in­hibitor in­to the fold, but what about high­ly tout­ed spar­tal­izum­ab?

5 years ago

#JPM21: Resh­ma Ke­wal­ra­mani is on the hunt for 'mid-to late-stage as­sets,' new tools to re­plen­ish Ver­tex pipeline

5 years ago

Glax­o­SmithK­line backs a pre­clin­i­cal ac­ne treat­ment from Eli­go Bio­science that us­es CRISPR to kill bac­te­ria

5 years ago

EQRx scores $500M to dri­ve its dis­rup­tive drug pric­ing mod­el and late-stage on­col­o­gy hope­fuls to mar­ket

5 years ago

Sanofi CEO Paul Hud­son’s lat­est M&A gam­bit adds new eczema drug in $1.5B buy­out. And he’s steer­ing back in­to a mar­ket mael­strom

5 years ago

Chimerix places its bets on On­co­ceu­tic­s' dopamine an­tag­o­nist for rare brain can­cer in quest to sal­vage its im­age

5 years ago

Mer­ck KGaA snaps up Ger­man CD­MO in boost to mR­NA port­fo­lio — in­clud­ing for Covid-19

5 years ago
Manufacturing

Der­mi­ra vets li­cense back can­di­dates from Eli Lil­ly to launch their own up­start

5 years ago
Startups

Bris­tol My­ers Squibb ices li­cens­ing pact with Ar­se­nal­Bio to draft its de­sign­er T cells in­to the sol­id tu­mor fight

5 years ago
R&D

EX­CLU­SIVE: Zai Lab’s Saman­tha Du scoops up Chi­na rights to an au­toim­mune drug with a hefty $175M li­cens­ing deal — heav­i­ly front­ed with cash and stock

5 years ago

So why is Alex­ion pay­ing $100M for a PRV as As­traZeneca lines up their $39B buy­out?

5 years ago
Pharma

Roche isn’t done lin­ing up new col­lab­o­ra­tions in the hot field of drug­ging RNA. Here’s one more

5 years ago

Edg­ing to­ward a piv­otal read­out, Bio­gen picks a new dis­cov­ery part­ner for oph­thalmic gene ther­a­py

5 years ago

Mil­len­do braces for deep cuts af­ter its last clin­i­cal ef­fort ends in de­feat and a last search for a way to end things

5 years ago

Ab­b­Vie bails on So­sei Hep­tares pact for nov­el neu­rol­o­gy can­di­dates in blow to dis­cov­ery out­fit's A-list Rolodex

5 years ago

Charles Riv­er bags an­ti­body dis­cov­ery-fo­cused Dis­tri­b­u­tion Bio for $104M, sig­nal­ing re­turn to pre-pan­dem­ic buy­out spree

5 years ago

In quick start to new year's M&A, Arvelle Ther­a­peu­tics hands reins to An­geli­ni as it nears EU ap­proval for cenoba­mate

5 years ago
R&D

A $6B CVR goes pfffft as the game clock runs out on a New Year's dead­line for Bris­tol My­er­s' liso-cel ap­pli­ca­tion

5 years ago

Phar­ma heavy­weight Pfiz­er step­ping in­to the prostate can­cer ring with Ab­b­Vie af­ter ink­ing a $4.2B al­liance with My­ovant

5 years ago
First page Previous page 80818283848586 Next page Last page
A service from the Financial Times